HWHG(SH:600079) Shang Hai Zheng Quan Bao·2025-11-28 20:13Group 1 - The core point of the announcement is that the company, Renfu Pharmaceutical Group Co., Ltd., is participating in the establishment of a private equity fund, the Ruicheng Venture Capital Fund, with a total initial investment of 250 million yuan, focusing on the high-tech industry in the health sector [2][4][5] - The company will contribute 75 million yuan, accounting for 30% of the total initial capital of the fund, and this investment constitutes a related party transaction due to the company's 32.25% ownership stake in Wuhan Ruicheng [2][4][5] - The investment has been approved by the company's general manager's office and does not require further approval from the board of directors or shareholders, as the transaction amount is below 0.5% of the company's latest audited net assets [3][33] Group 2 - The Ruicheng Venture Capital Fund aims to invest in high-tech industries within the health sector, including biomedicine and medical devices, leveraging industry resources and synergies to accelerate innovation and commercialization [4][5][22] - The fund's management structure includes a decision-making committee composed of five members, with investment decisions requiring a two-thirds majority vote [22] - The fund's management fee is set at 2% of the total capital during the investment period and 1.5% during the exit period, with specific payment schedules outlined [23][24] Group 3 - The company has a history of minimal related party transactions with Wuhan Ruicheng, amounting to 35,900 yuan in the past 12 months, which is negligible compared to its net assets [6][32] - The company emphasizes that this investment will not affect its main business operations or financial performance significantly, and it will not harm the interests of shareholders [31]